2023
Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
Brunner A, Platzbecker U, DeZern A, Zeidan A. Are We Ready For “Triplet” Therapy in Higher-Risk MDS? Clinical Hematology International 2023, 5: 23-32. PMID: 37933301, PMCID: PMC10625655, DOI: 10.46989/001c.88301.Peer-Reviewed Original ResearchAcute myeloid leukemiaCombination chemotherapyPatient populationOnly disease-modifying therapyNovel combination chemotherapyOngoing therapeutic challengeOlder patient populationUnique patient populationDisease-modifying therapiesCurrent treatment paradigmsTherapeutic challengeTreatment paradigmEffective therapyMyeloid leukemiaNew therapiesAppropriate endpointsTherapyChemotherapyComorbiditiesPatientsTransplantNeoplasmsLeukemiaPopulationDecitabineOlder patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access
2021
Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
Dinan M, Wilson L, Greiner M, Spees L, Pritchard J, Zhang T, Kaye D, George D, Scales C, Wheeler S. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 280-280. DOI: 10.1200/jco.2021.39.6_suppl.280.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsDisease-specific survivalRenal cell carcinomaCell carcinomaPatient populationSEER-Medicare patientsDisease-specific mortalityNumber of comorbiditiesOlder patient populationProgression-free survivalReal-world adherenceRandomized clinical trialsTreatment of patientsAnalysis of patientsProportion of daysRCC-specific mortalityMinimum effective doseSignificant reductionOAA therapyCause mortalityElderly patientsFavorable survivalMetastatic RCCMultivariable analysis
2018
Clinical End Points of Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Patients <65 Years of Age (From the National Inpatient Sample Database)
Ando T, Akintoye E, Holmes A, Briasoulis A, Pahuja M, Takagi H, Schreiber T, Grines C, Afonso L. Clinical End Points of Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Patients <65 Years of Age (From the National Inpatient Sample Database). The American Journal Of Cardiology 2018, 122: 279-283. PMID: 29880287, DOI: 10.1016/j.amjcard.2018.03.356.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAortic ValveAortic Valve StenosisCause of DeathFemaleFollow-Up StudiesHospital MortalityHumansIncidenceInpatientsLength of StayMaleMiddle AgedPostoperative ComplicationsPropensity ScoreRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTranscatheter Aortic Valve ReplacementUnited StatesYoung AdultConceptsSurgical aortic valve replacementTranscatheter aortic valve implantationAortic valve replacementShorter hospital stayAortic valve implantationHospital mortalityHospital stayValve replacementValve implantationNational Inpatient Sample databaseSafe alternativeAcute kidney injuryOlder patient populationClinical end pointsAcute myocardial infarctionPropensity score analysisYears of agePostprocedure strokeKidney injuryValve surgeryVascular complicationsMajor complicationsPacemaker implantationPatient populationMyocardial infarctionAntiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. Journal Of Clinical Medicine 2018, 7: 74. PMID: 29642547, PMCID: PMC5920448, DOI: 10.3390/jcm7040074.Peer-Reviewed Original ResearchAcute coronary syndromePercutaneous coronary interventionDAPT durationDuration of DAPTOlder patient populationCoronary artery diseasePotent antiplatelet agentsMajor societal guidelinesNovel anticoagulant drugsAntiplatelet therapyCoronary syndromeMultiple comorbiditiesP2Y12 inhibitorsTriple therapyCoronary interventionAntiplatelet agentsArtery diseasePatient populationSocietal guidelinesAnticoagulant drugsOptimal durationClinical decisionAvailable evidenceTherapyNew stent
2010
Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Saba H, Klein C, Mehta P, Hayes T, Roodman D, Lichtenstein A. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood 2010, 116: 3061. DOI: 10.1182/blood.v116.21.3061.3061.Peer-Reviewed Original ResearchEntity's Board of DirectorsGrade 1 neuropathyMultiple myeloma patientsSignificant co-morbiditiesOverall response rateCo-morbiditiesMyeloma patientsNewly-diagnosed multiple myeloma patientsNewly diagnosed multiple myeloma patientsEvaluate overall response rateAutologous stem cell transplantationElevation of serum creatinineResponse rateGrade 3 neuropathyRegimen of bortezomibDose of bortezomibAssociated with side effectsStem cell transplantationImproved toxicity profileProportion of patientsOlder patient populationHistory of cancerAdvisory CommitteeWeekly bortezomibBortezomib dose
2009
Days of Delirium Are Associated with 1-Year Mortality in an Older Intensive Care Unit Population
Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of Delirium Are Associated with 1-Year Mortality in an Older Intensive Care Unit Population. American Journal Of Respiratory And Critical Care Medicine 2009, 180: 1092-1097. PMID: 19745202, PMCID: PMC2784414, DOI: 10.1164/rccm.200904-0537oc.Peer-Reviewed Original ResearchConceptsICU deliriumPatient populationNumber of daysOlder intensive care unit patientsIntensive care unit populationAdverse long-term outcomesIntensive care unit patientsRelevant covariatesUrban acute care hospitalDuration of deliriumPost-ICU admissionConfusion Assessment MethodOlder patient populationProspective cohort studyCare unit patientsSeverity of illnessLong-term outcomesDays of deliriumPsychoactive medication useAcute care hospitalsChart review methodImportant health outcomesICU admissionCohort studyICU population
2004
The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. DOI: 10.1097/01.jam.0000129822.54487.14.Peer-Reviewed Original ResearchLong-term care settingsOlder patientsAtypical antipsychoticsCare settingsNeurodegenerative disordersSide effectsDouble-blind placebo-controlled trialHigh-potency conventional antipsychoticsLong-term care patientsOpen-label studyPlacebo-controlled trialNewer atypical antipsychoticsOlder patient populationUse of quetiapineUse of risperidoneExtrapyramidal side effectsAtypical antipsychotic medicationsConventional antipsychoticsCare patientsTardive dyskinesiaNovel antipsychoticsAntipsychotic medicationPatient populationPsychopharmacologic agentsAgitation symptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply